SYNAKIS
Synakis patented a biodegradable hydrogel vitreous substitute that is injectable, non-cytotoxic in vitro and in vivo, low-swelling, stable, and optically transparent with a refractive index and density similar to those of the native vitreous.
SYNAKIS
Social Links:
Industry:
Medical Medical Device
Founded:
2019-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.synakis.com
Total Employee:
1+
Status:
Active
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Osciflex
Osciflex system imitates nature’s process to prevent deadly blood clots.
sovaSage
SovaSage is a digital healthcare platform used to come up with the treatment of sleep apnea patients and other chronic conditions.
Tarsa Therapeutics
Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.
Current Employees Featured
Founder
Investors List
UTEST
UTEST investment in Pre Seed Round - Synakis
More informations about "Synakis"
Synakis - Crunchbase Company Profile & Funding
Synakis patented a biodegradable hydrogel vitreous substitute that is injectable, non-cytotoxic in vitro and in vivo, low-swelling, stable, and optically transparent with a refractive index and …See details»
Synakis
Synakis Solutions for the Eye. Biomaterial-based Treatments for Ocular Conditions. Synakis is a pre-clinical biotech startup developing biomaterial-based treatments for ocular injuries and diseases, including retinal detachment and …See details»
SYNAGIS (palivizumab) | Parent & Caregiver Website
AstraZeneca has transferred all rights to SYNAGIS (palivizumab) to another manufacturer, Swedish Orphan Biovitrum AB (SOBI), in January of 2019. If you need SYNAGIS support, …See details»
Synakis - VentureRadar
"Synakis is a pre-clinical biotech startup focused on developing innovative biomaterial-based treatments for ocular injuries and diseases such as retinal detachment and glaucoma.See details»
Treatment for Highest-Risk RSV Patients | SYNAGIS®
These are not all the possible risks associated with SYNAGIS. Please see full Prescribing Information for SYNAGIS, including Patient Information. To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 …See details»
Swedish Orphan Biovitrum - Crunchbase Company …
Synagis: A preventive treatment for serious lower respiratory tract infections caused by respiratory syncytial virus (RSV) in high-risk infants and young children. Kineret: A treatment for cryopyrin-associated periodic syndrome, …See details»
Contact Sobi | SYNAGIS (palivizumab)
AstraZeneca has transferred all rights to SYNAGIS (palivizumab) to another manufacturer, Swedish Orphan Biovitrum AB (SOBI), in January of 2019. If you need SYNAGIS support, …See details»
University of Toronto Entrepreneurship | Synakis
Synakis has developed a novel ocular hydrogel that is injectable, biocompatible, biodegradable, low swelling and transparent. Our biomaterial can be used as a vitreous substitute for vitreoretinal surgery and to deliver engineered …See details»
Cheaper version of protective preemie drug in …
Apr 6, 2017 The World Health Organization has recruited companies in low- and middle-income countries to develop and manufacture a cheaper version of Synagis, which is used to protect premature babies from a ...See details»
SYNAGIS (palivizumab) for Prevention of Severe RSV Disease
How does SYNAGIS help? SYNAGIS gives babies who are born prematurely (at or before 35 weeks, and who are 6 months of age or less at the beginning of RSV season) the virus …See details»
Synakis - Overview, News & Similar companies | ZoomInfo.com
View Synakis (www.synakis.ca) location in Ontario, Canada , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
Parent/Caregiver Consent Form - SYNAGIS® | HCP
• Call SYNAGIS CONNECT at 1-833-SYNAGIS (1-833-796-2447) Monday through Friday 8 am to 8 pm ET, or visit Synagis.com • Fax completed form to SYNAGIS CONNECT at 1-800-201 …See details»
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION …
SYNAGIS 1.0 mL solution for injection is supplied as a single-use 3 mL vial containing 1 mL of SYNAGIS solution for injection with a concentration of 100 mg/mL. SYNAGIS does not contain …See details»
Palivizumab - Wikipedia
Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial …See details»
All About Synagis: The RSV Shot For Babies - Romper
Feb 20, 2024 Synagis’ effectiveness has not been studied in a large clinical setting, however, data suggests that it is effective in both preventing serious disease and lowering …See details»
from turning a welcome home into - SYNAGIS
After getting SYNAGIS, call your child’s healthcare provider or get medical help right away. Learning more is a great first step to protecting your baby. In this brochure, you’ll find …See details»
Palivizumab Prophylaxis in Infants and Young Children at …
Jun 26, 2023 The palivizumab package insert states “Synagis is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of RSV disease.” …See details»
Protecting your vulnerable baby from severe RSV disease - SYNAGIS
Please see full Prescribing Information for SYNAGIS, including Patient Information. INDICATION SYNAGIS, 50 mg and 100 mg for injection, is a prescription medication that is used to help …See details»
AZ, Sanofi prep filings for one-shot RSV antibody after trial win
Dec 11, 2024 Sobi acquired rights to Synagis from AZ in 2019, taking control of a drug that had made more than $1 billion in annual sales at its peak but had started to decline after its …See details»
What's RSV? What are RSV Risks & Symptoms? - SYNAGIS
What is SYNAGIS ® (palivizumab)? SYNAGIS is a prescription medication that is injected (50 mg and 100 mg) in certain children to help prevent serious lung disease caused by respiratory …See details»